Weekly Subcutaneous <scp>VK2735</scp> , a <scp>GIP</scp> / <scp>GLP</scp> ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week <scp>VENTURE</scp> Study

Authors

Institutions

Publication Details

Journal
Obesity
Published
2026-01-08
DOI
https://doi.org/10.1002/oby.70106
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Brian Lian, John Pullman, Summer Ji, Parke Hedges et al.
Obesity
Diabetes Treatment and Management
article

Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Brian Lian, John Pullman, Summer Ji, Parke Hedges, Naim Alkhouri, Phillip D. Toth, Scott Stubbe, Bradley Freilich, Joel Neutel
article en

Abstract

No abstract available for this paper.
ObesityVol. 34(3)
Lake County (US), Viking Therapeutics (United States) (US), Midwest Eye Institute (US), Conceptual Mindworks (United States) (US), Kansas City Research Institute (US), Louisville Metabolic and Atherosclerosis Research Center (US), Nagoya Kyouritsu Hospital (JP), Montana Technological University (US)
Openalex Percentile: Top 93%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.